P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational studyECCO '17 Barcelona
2017
P598: Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?ECCO '17 Barcelona
2017
P599: Home testing for faecal calprotectin: follow-up results from the first UK trialECCO '17 Barcelona
2017
P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel diseaseECCO '17 Barcelona
2017
P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?ECCO '17 Barcelona
2017
P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centreECCO '17 Barcelona
2017
P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN studyECCO '17 Barcelona
2017
P604: Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitisECCO '17 Barcelona
2017
P605: Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISAECCO '17 Barcelona
2017
P606: Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNFα in response to infliximab in Crohn's diseaseECCO '17 Barcelona
2017
P607: Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide studyECCO '17 Barcelona
2017
P608: New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort studyECCO '17 Barcelona
2017
P609: A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomesECCO '17 Barcelona
2017
P610: Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept studyECCO '17 Barcelona
2017
P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapyECCO '17 Barcelona
2017
P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activityECCO '17 Barcelona
2017